The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I/II study of letrozole and sorafenib as first-line therapy of hormone-receptor positive (HR+) metastatic breast cancer (MBC).
Antoinette R. Tan
Research Funding - Bayer
Serena Tsan-Lai Wong
No relevant relationships to disclose
Robert D. Warren
No relevant relationships to disclose
Jennifer Eng-Wong
No relevant relationships to disclose
Minetta C. Liu
No relevant relationships to disclose
Amelia Bruce Zelnak
No relevant relationships to disclose
Yong Lin
No relevant relationships to disclose
Weichung Shih
No relevant relationships to disclose
Shridar Ganesan
No relevant relationships to disclose
Generosa Grana
No relevant relationships to disclose
Claudine Isaacs
Consultant or Advisory Role - Novartis
Deborah Toppmeyer
Stock Ownership - Novartis (I)